newsfilter
← Latest News
Earnings Call Transcripts·

Septerna - 1781718 - SEPTERNA INC

  • Explicit Guidance:

    • Clinical Trial Timelines:
      • SCP-479 (Hyperparathyroidism) Phase 1 data readout expected in Q1 2027; Phase 1 trial estimated to include ~150 subjects in Australia with a 14-day multiple ascending dose period to reach steady state.
      • SCP-204 (Graves' disease/Thyroid Eye Disease) Phase 1 clinical initiation targeted for Q1 2027, with healthy volunteer data expected prior to the end of 2027.
      • Phase 2 trial for SCP-479 targeted for the second half of 2026, contingent on completion of chronic toxicology studies.
    • Specific Clinical Endpoints:
      • SCP-479 Phase 1: Aiming for endogenous PTH reduction of ~50% and serum calcium increase of ~0.5 mg/dL (starting dose benchmark) and up to 1 mg/dL (high dose).
      • SCP-204 Phase 1: Targeting elevation of endogenous TSH and suppression of thyroid hormones; preclinical dosing demonstrated T4 normalization at 1–3 mg/kg and suppression at 10 mg/kg.
  • Business-Segment Outlook:

    • SCP-479 (Hyperparathyroidism): Positioned to expand the treatable population beyond severe patients currently restricted to daily injections (Urovipath) to include moderate patients; potential to replace calcium/vitamin D supplements as standard of care.
    • SCP-204 (Thyroid Disease): Aiming to address unmet needs in Graves' disease (high relapse rates with current antithyroid drugs) and Thyroid Eye Disease (limited options for mild to moderate patients).
    • SCP-631 (MRGPRX2/Mast Cell): Shifting strategy from large Phase 2 trials in Chronic Spontaneous Urticaria (CSU) to focused, smaller "signal-finding" studies in new indications including migraine, interstitial cystitis, and asthma.
    • Osteoporosis Program: Developing a distinct short-acting PTH agonist pipeline to leverage anabolic bone formation effects, differentiated from the long-acting SCP-479.
    • Novo Partnership: Collaboration launched in mid-2025 covers five targets; the first development candidate was selected last quarter, with plans to advance forward (no specific timing for IND filing provided).
  • Market and Competitive Outlook:

    • Competitive Landscape (Hyperparathyroidism): Differentiates from Novo Nordisk's Encalerate (calcium-sensing receptor agonist) by targeting the PTH receptor directly; Encalerate requires intact parathyroid tissue (unsuitable for post-surgical patients where SEP-479 focuses).
    • Addressable Market: Estimates ~70,000–80,000 patients in the U.S. with post-surgical hypoparathyroidism; current standard of care (daily injectable Urovipath) limits treatment to severe cases, creating an opportunity for oral therapy uptake.
    • Graves' Disease Landscape: Highlights a lack of novel development in years for this indication, with significant relapse rates for current antithyroid therapies.
  • Macro / Industry Outlook:

    • Regulatory Path: No specific regulatory changes cited, but the company relies on existing precedents from injectable PTH peptides (Urovipath) for dosing, titration protocols, and safety monitoring in healthy volunteers as a predictor for patient efficacy.
    • Pricing Strategy: Management defers pricing discussions until benefit-to-patient data is established, anticipating that oral therapies in rare diseases may offer pricing value through improved convenience, though no specific figures are projected.
  • Strategic Initiatives:

    • Platform Expansion: Leveraging the "Native Complex Platform" to discover oral small molecules for difficult GPCR targets (PTH1R, TSHR) where historical small-molecule success has been rare.
    • Pipeline Progression:
      • Advancing SCP-479 from Phase 1 (ongoing) to Phase 2 by H2 2026.
      • Initiating SCP-204 Phase 1 in Q1 2027.
      • Selecting first candidate from the Novo collaboration for advancement.
    • Clinical Trial Design: Planning to enroll patients from Phase 3 trials into open-label extensions immediately following Phase 2 chronic toxicology studies to allow long-term continuation for benefiting patients.
  • Risks and Headwinds to Outlook:

    • Mechanism Uncertainty: Development of oral small molecules for GPCRs mimicking peptide function has historically failed for many companies; success is not guaranteed.
    • Toxicology Risks: SCP-204 preclinical studies showed "exaggerated on-target pharmacology" (hypothyroidism), which may present challenges for tolerability or dosing in patients.
    • Clinical Readiness: SCP-479 Phase 1 is in healthy volunteers; while biological mechanisms are consistent with patients, clinical translation remains unproven until patient data is acquired.
    • Competitive Dynamics: Potential competition from other oral PTH candidates (e.g., Encalerate) and the ultimate market acceptance of mechanism-based alternatives in rare disease spaces.
  • Management Tone on the Future:

    • Confidence: High confidence in the platform's ability to solve historical "undruggable" challenges for PTH1R and TSHR; describes SCP-479 and SCP-204 as moving "quite nicely."
    • Hedges: Explicit caution regarding pricing discussions; acknowledges that the Phase 1 healthy volunteer data is a "proof-of-concept" and that patient titration protocols must be rigorously developed.
    • Strategic Shift: Adoption of a "smaller, signal-finding" approach for SCP-631 (migraine) rather than immediate large-scale trials, indicating a cautious, data-driven stance on new indications following initial CSU setbacks.
  • Miscellaneous:

    • Pharmacokinetics: SCP-479 projected half-life of 3–4 days (observed at upper end of 40–80h prediction); SCP-204 projected half-life of 20–40 hours. Both targeted for once-daily oral dosing.
    • Preclinical Differentiation: SCP-204 demonstrates dose selectivity to avoid FSH/LH receptors; SCP-479 achieves full mimicry of PTH peptide activity in preclinical models.
Company
SEPTERNA INC
Keywords
SEPTERNA INC